home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

23.08 -1.80 (-7.23%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

2 Breakout Growth Stocks to Buy for the Long Haul ↗

March 03, 2023

These two stocks are entirely different, but they both make shareholders richer.

Via The Motley Fool

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 15, 2023

March 01, 2023

The Company Will Host a Conference Call and Webcast on March 16, 2023, at 8:30 AM ET

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

7 Smart Stock Picks for Cautious Investors ↗

February 28, 2023

As market volatility continues, consider playing it safe with these seven high-quality stocks for cautious investors.

Via InvestorPlace

Catalyst Pharmaceuticals to Ring the Nasdaq Closing Bell in Honor of International Rare Disease Day

February 22, 2023

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Here's How Much $1000 Invested In Catalyst Pharmaceuticals 15 Years Ago Would Be Worth Today ↗

January 25, 2023

Via Benzinga

$1000 Invested In This Stock 10 Years Ago Would Be Worth $27,000 Today ↗

January 23, 2023

Via Benzinga

Analyst Expectations for Catalyst Pharmaceuticals's Future ↗

January 19, 2023

Via Benzinga

Catalyst Pharma Reveals Interim Q4 Earnings, Says Well Positioned For 2023 ↗

February 07, 2023

Via Benzinga

Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue Guidance

February 07, 2023

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

The 7 Best Growth Stocks to Buy for February 2023 ↗

February 06, 2023

Some of the best growth stocks are lesser-known names that have the ability to provide tremendous long-term upside for investors.

Via InvestorPlace

Stock Market Rally Powers Higher Amid Big Earnings From Tesla, Boeing, Microsoft, American Express: Weekly Review ↗

January 27, 2023

Stocks reacted well to uneven earnings and economic reports.

Via Investor's Business Daily

Down 30% in a Day, Is Catalyst Pharmaceuticals Doomed? ↗

January 26, 2023

Things aren't as bad as they might seem.

Via The Motley Fool

How Former IBD 50 Leader Catalyst Pharma Is Trying To Claw Back From A 29% Setback ↗

January 25, 2023

Catalyst is adding to its portfolio with a $160 million deal.

Via Investor's Business Daily

Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII

January 25, 2023

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Pliant Therapeutics Gaps 34% Higher: More Upside To Come?

January 25, 2023

Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.

Via MarketBeat

Nasdaq Rises 1.5%; Pliant Therapeutics Shares Spike Higher ↗

January 23, 2023

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 150 points on Monday. The Dow traded up 0.46% to 33,527.51 while the NASDAQ rose 1.55% to 11,313.03. The...

Via Benzinga

Why Evoqua Water Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

January 23, 2023

Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 444.4% to $1.47 after the company announced it successfully completed the review of results from Milestone 7, a phase of its...

Via Benzinga

Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra

January 23, 2023

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Dow, Nasdaq Boasting Triple-Digit Midday Lead ↗

January 23, 2023

Investors seem intent on leaving last week's losses behind, as earnings season heats up.

Via Talk Markets

12 Health Care Stocks Moving In Monday's Intraday Session ↗

January 23, 2023

Via Benzinga

Dow Jumps Over 300 Points; Crude Oil Up 1% ↗

January 23, 2023

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 30 points on Monday. The Dow traded up 0.94% to 33,687.69 while the NASDAQ rose 1.93% to 11,355.16. The S&P 500...

Via Benzinga

Catalyst Pharmaceuticals, Xylem And Other Big Stocks Moving Lower On Monday ↗

January 23, 2023

U.S. stocks traded higher, with the Dow Jones gaining over 300 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Catalyst Pharma Shares Take A Hit As Teva Files For Generic Version Of Its Lead Product ↗

January 23, 2023

Via Benzinga

US Stocks Mostly Higher; Synchrony Financial Earnings Top Views ↗

January 23, 2023

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 90 points on Monday.

Via Benzinga

No. 1 IBD 50 Stock Catalyst Tanks As Teva Looks To Knock Off Its Only Product ↗

January 23, 2023

Shares have sat atop the IBD 50 for weeks, have perfect ratings and recently hit a profit-taking zone.

Via Investor's Business Daily

Why Catalyst Pharmaceuticals Shares Are Moving ↗

January 23, 2023

Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) shares are trading lower by 13.46% to $18.00 Monday morning after Teva Pharmaceuticals stated it plans to sell a generic version of Catalyst's FIRDAPSE in...

Via Benzinga

Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE®

January 23, 2023

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

2 Biotechs Making Waves With A Single Product in their Pipeline

January 11, 2023

Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise.

Via MarketBeat

IDEXX Laboratories Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗

January 09, 2023

IDEXX Laboratories sees its Relative Strength Rating reach the 80-plus level.

Via Investor's Business Daily

Top Picks For 2023: Catalyst Pharmaceuticals - Sunday, Jan. 8 ↗

January 08, 2023

For a growth-oriented choice for the new year, I'm going with under-the-radar company, Catalyst Pharmaceuticals. Let's take a look at the company's fundamentals, technicals, and institutional support...

Via Talk Markets

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com